ARHGAP5 antisense RNA 1 (ARHGAP5-AS1)

ARHGAP5 antisense RNA 1 (ARHGAP5-AS1) is a long non-coding RNA transcribed antisense to the ARHGAP5 gene. It displays context-dependent roles in cancer: as a metastasis suppressor in breast cancer—where it stabilizes SMAD7 and inhibits TGF-β signaling, thereby impeding cell migration—and as a promoter of chemoresistance in gastric cancer, in which its upregulation activates and stabilizes ARHGAP5 by recruiting the m6A-methyltransferase METTL3, with its expression regulated by autophagy. In lung cancer, it is part of a biomarker signature relevant for diagnosis and prognosis. ARHGAP5-AS1 is not a typical protein target but is increasingly investigated for its role in cancer biology and potential as a biomarker. ARHGAP5-AS1 is not a receptor, enzyme, transporter, or classical drug target but is involved in cancer progression and drug resistance. Its therapeutic relevance lies primarily as a biomarker and as a regulator of chemoresistance, making the ARHGAP5-AS1/ARHGAP5 axis a possible future therapeutic target in precision oncology. No drugs are known to directly target ARHGAP5-AS1, and mechanisms for potential future interventions would involve modulation of its RNA levels or interactions.

Other names

C14orf128MGC15504Putative uncharacterized protein ARHGAP5-AS1ARHGAP5 antisense gene protein 1

Not directly targeted by drugs; acts by modulating gene expression and protein stability (SMAD7, ARHGAP5). Drug resistance via activation and stabilization of ARHGAP5 and blockade of apoptosis.